280 related articles for article (PubMed ID: 33726903)
1. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial.
Shim CY; Seo J; Kim YJ; Lee SH; De Caterina R; Lee S; Hong GR;
J Thorac Cardiovasc Surg; 2023 Jan; 165(1):58-67.e4. PubMed ID: 33726903
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation.
Skogseid EL; Batra G; Westerbergh J; Held C; Christersson C
Open Heart; 2024 Jan; 11(1):. PubMed ID: 38290732
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial.
Izumi C; Amano M; Fukushima S; Yaku H; Eishi K; Sakaguchi T; Minami M; Yamamoto H; Onda K; Omae K
Cardiovasc Drugs Ther; 2024 Jun; ():. PubMed ID: 38913220
[TBL] [Abstract][Full Text] [Related]
7. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study.
Eikelboom R; Whitlock RP; Sibilio S; Nguyen F; Perez R; Weitz JI; Belley-Cote E
Cardiovasc Drugs Ther; 2024 Feb; 38(1):109-117. PubMed ID: 36121587
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
10. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.
Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E
Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366
[TBL] [Abstract][Full Text] [Related]
12. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Pasciolla S; Zizza LF; Le T; Wright K
Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
[TBL] [Abstract][Full Text] [Related]
14. New Oral Anticoagulant Versus Vitamin K Antagonists for Thoracoscopic Ablation in Patients With Persistent Atrial Fibrillation: A Randomized Controlled Trial.
Lee Y; Jeong DS; Ahn J; Park KM; Park SJ; Kim JS; On YK
Semin Thorac Cardiovasc Surg; 2023; 35(2):268-274. PubMed ID: 34879226
[TBL] [Abstract][Full Text] [Related]
15. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.
Russo V; Attena E; Mazzone C; Esposito F; Parisi V; Bancone C; Rago A; Nigro G; Sangiuolo R; D' Onofrio A
Semin Thromb Hemost; 2018 Jun; 44(4):364-369. PubMed ID: 29304513
[TBL] [Abstract][Full Text] [Related]
16. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
17. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
18. Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis.
Cardoso R; Ternes CMP; Justino GB; Fernandes A; Rocha AV; Knijnik L; d'Avila A; Lopes RD
Am J Med; 2022 Feb; 135(2):228-234.e1. PubMed ID: 34634252
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial.
Rafiq S; Steinbrüchel DA; Lilleør NB; Møller CH; Lund JT; Thiis JJ; Køber L; Olsen PS
Thromb Res; 2017 Feb; 150():104-110. PubMed ID: 27914653
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
Guimarães HP; Lopes RD; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Hoffmann-Filho CR; de Lemos Soares Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Kojima FCS; Damiani L; Santos RHN; Valeis N; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Alexander JH; Pavanello R; Cavalcanti AB; Berwanger O;
N Engl J Med; 2020 Nov; 383(22):2117-2126. PubMed ID: 33196155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
